RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter ended September 30, 2002 (Q2 FY03)
Filing Date: November 7, 2002 (covering events through October 2002)

The company commenced reporting financials on a consolidated basis under US GAAP starting Q1 FY03. Consequently, current quarter consolidated US GAAP financials are not directly comparable with earlier standalone Indian GAAP releases. The filing includes unaudited financial results, regulatory updates, and corporate news.

Key Financial Metrics

Segment Performance:

• Active Pharmaceutical Ingredients (API): Sales increased 35% to Rs. 1,739 million. International sales grew 55% to Rs. 1,244 million.
• Branded Formulations: Sales increased 18% to Rs. 2,021 million. India sales grew 19.9% (vs. 10.5% industry growth); International sales grew 12%.
• Generics: Reported revenue decreased to Rs. 1,021 million from Rs. 1,938 million due to the absence of Fluoxetine exclusivity revenue in the current period.

Liquidity and Debt: The filing text does not provide specific values for cash flow, debt levels, or liquidity ratios.

Material Changes vs. Prior Period

The reported decline in revenue (-4%), operating income (-58%), and net income (-55%) is primarily attributed to the absence of one-time revenue from Fluoxetine in the current quarter. In Q2 FY02, the company held an 180-day marketing exclusivity for Fluoxetine, generating Rs. 1,724 million in revenue.

Adjusted Performance (Excluding Fluoxetine):

• Revenue: Grew 45% year-over-year.
• Net Income: Grew 118% year-over-year.
• EBITDA: Increased 89% year-over-year.
• Generics Segment: Excluding Fluoxetine, revenues increased by 377% (Rs. 807 million growth).

Operating expenses increased 59% to Rs. 1,718 million, and gross margin decreased from 65% to 54%.

Guidance, Outlook, Risks, and Unusual Items

Regulatory Milestones:

• Amlodipine Maleate: Received an "Approvable" letter from the US FDA. Final approval is contingent on resolving chemistry manufacturing controls, labeling, and a patent term extension litigation with Pfizer. Launch expected August 26, 2003, pending litigation outcome.
• Omeprazole: US District Court ruled that Dr. Reddy's infringed on two formulation patents. The company intends to appeal the decision.
• ANDA Filings: Filed one new Abbreviated New Drug Application (ANDA) with Para IV certification. Total pending ANDAs at USFDA: 15.

Corporate Initiatives:

• Launched the "Dr. Reddy's Foundation for Health Education" to train patient educators.
• Launched a fifth Breast Cancer Helpline in Mumbai.
• Selected as one of Forbes Global's 200 Best Small Companies for 2002.

Risks and Contingencies:

• Patent Litigation: Ongoing litigation with Pfizer regarding Amlodipine and AstraZeneca regarding Omeprazole poses risks to product launches and market access.
• Forward-Looking Statements: Results may differ materially due to global economic conditions, market acceptance, and technological changes.

Investor Verification Checklist

• Adjusted Growth Metrics: Verify the company's "organic" growth rates (excluding Fluoxetine) to assess underlying business health versus reported GAAP declines.
• Patent Litigation Status: Monitor the outcome of the Pfizer (Amlodipine) and AstraZeneca (Omeprazole) lawsuits, as these directly impact future revenue streams.
• ANDA Pipeline: Track the approval status of the 15 pending ANDAs at the USFDA, particularly the new Para IV certification filed in the quarter.
• Consolidated Reporting: Ensure future comparisons account for the shift from standalone Indian GAAP to consolidated US GAAP reporting.
• Shareholding Changes: Note that Life Insurance Corporation of India (LIC) holds 5.52% of the paid-up capital as of October 18, 2002.